Compare Charles River Laboratories Intl. Inc (CRL) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Visa Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Visa Inc trades at $355.84 (market cap $677.06B). The key difference: Visa Inc is far larger — about 60.8× Charles River Laboratories Intl. Inc's market cap, and Visa Inc pays a 0.75% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | V | |
|---|---|---|
Market Cap | $11.14B | $677.06B |
Sector | Health | Financials |
52-Week High | $233.60 | $362.13 |
52-Week Low | $145.57 | $295.52 |
Enterprise Value | $14.00B | $687.65B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Visa (V) trades at $357.75, up 2.52% today, near its pivot point of $357 with bullish technical signals and strong analyst consensus. The company reported Q1 2026 EPS of $3.31, beating estimates, and maintains robust profitability with a 51.68% net income margin. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth in digital payments.
Outlook remains positive with a consensus price target of $394.50, implying 10% upside, supported by earnings momentum and innovation in payment technology. Risks include competitive pressures from fintech and regulatory scrutiny, but institutional holdings and a debt-to-asset ratio of 25.26% reflect financial stability. The stock offers a compelling growth profile with manageable risks for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
